September 10, 2024
Alopexx Announces Collaboration with Bharat Biotech for the Development and Commercialization of Broad-Spectrum Anti-Microbial Vaccine AV0328
September 06, 2024
Alopexx Announces Investment from Biotech Consortia, Inc.
October 12, 2023
Alopexx to Present Data on F598, a Novel, Broad-Spectrum Immunotherapeutic at IDWeek 2023
October 11, 2023
Alopexx Announces Presentation at ID Week 2023
Dr. Gerald Pier was awarded two grants in May 2023, one from the Cystic Fibrosis (CF) Foundation to study the “Impact of microbiota-derived inflammatory factors on cystic fibrosis related diabetes” for $223,462 and the second from the National Institutes of Allergy and Infectious Diseases/National Institute of Health for $264,708 to study the “Development of a model of Gonococcal conjunctivitis for vaccine evaluations.” In both studies the potential efficacy of the PNAG vaccine to prevent CF related diabetes and gonococcal infections will be investigated.
Alopexx Expands Leadership Team with Appointment of Thomas T. Thomas as Chief Financial Officer
Dr. Gerald Pier Presents Preclinical Data at ASM Microbe, June 10th, 2022, showing “Vaccination Against The Broadly-Expressed Microbial Antigen PNAG Prevents Cognitive Decline In The APP-PS1 Mouse Model Of Alzheimer’s Disease”.
Dr. Colette Cywes-Bentley and Dr. Michael Whalen were Awarded $748,114 from the Department of Defense to Investigate the Role and Targeting of PNAG in Alzheimer’s Disease-Related Pathology Following Traumatic Brain Injury. Project to start by September, 2023.
Dr. Colette Cywes-Bentley and Dr. Gerald Pier were Awarded $245,324 from The Infectious Diseases Society of America Foundation to Investigate the Mechanism of How PNAG-Microbial Material Impacts Neuronal Tissue. Project started 01.01.22.
Dr. Daniel Vlock Presents at the 3rd Annual Vaccine World Asia Congress, November 17, 2021. The title of the talk was “Synthetic Oligosaccharide-Conjugate Vaccine AV0328 - A Novel Broad-Spectrum Vaccine for the Prevention of Serious Bacterial, Fungal and Protozoal Infections”.
Dr. Gerald Pier and Dr. Colette Cywes-Bentley Receives $75,000 Grant from President and Fellows of Harvard College to study the Role of the Borrelia Surface Polysaccharide PNAG in Virulence and Immunity in Lyme Disease. Project started 09.01.21.
Dr. Gerald Pier and Dr. Colette Cywes-Bentley Receives $362,174 Grant from the Alzheimer’s Disease Research Foundation to Validate that Immunotherapies Targeting the Conserved Microbial Surface Polysaccharide, poly-N-acetyl glucosamine (PNAG), Can Prevent Cognitive in a Murine Model of Alzheimer’s Disease. Project started 08.30.21.